Cancerkin’s News Update…
Cancerkin in East London
After another successful complementary therapy session at the Bromley-By-Bow Community Centre earlier this month, Cancerkin was back at St Joseph’s Hospice in Hackney on 23 April for our monthly session. Patients benefited from a variety of therapies, including one to one sessions of massage, reiki and reflexology and group sessions of pilates, tai chi and art therapy. 19 women with cancer attended and many commented on the warm and welcoming atmosphere of the day. This was all topped off by a gift of delicious sweet rice from one of our attendees! We would like to thank the staff of St Joseph’s and Bromley-By-Bow as always for their help in providing wonderful venues.
Mr Tim Davidson at Patient Support Group – 24 April 2012
On Tuesday, Mr Tim Davidson ChM, MRCP, FRCS, Consultant Breast Surgeon at the Royal Free Hospital and Cancerkin’s Medical Director gave a talk to a packed out audience at our monthly patient support group. He gave a very helpful overview of all the most commonly asked questions about breast cancer and its treatment, including why some patients undergo a mastectomy and some a lumpectomy, the pros and cons of reconstructive surgery and an explanation of the fascinating research published last week by Cancer Research UK which has re-categorised breast cancer into 10 different subtypes. Many participants took the opportunity to ask questions and we would like to thank Mr Davidson for sharing his time and expertise with us in what was an extremely interesting and informative meeting.
If you are interested in finding out more about upcoming support groups, please contact our Patient Support Manager Alice on email@example.com.
In the news…
Breast cancer genes and prostate cancer…
Women with a family history of breast cancer are at a much higher risk of developing the disease. In those who have inherited a faulty BRCA1 gene, there is a six in ten chance of developing the disease, compared with women who do not carry the faulty gene and have around a one in eight chance. A new piece of research conducted by scientists at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust has found that men who carry the faulty BRCA1 breast cancer gene are at a higher risk of developing prostate cancer. The study’s results, published in the British Journal of Cancer, showed that men carrying the gene had a one in 11 chance of developing the disease by the age of 65. Following the results, researchers suggest that men who have a strong family history of either breast or prostate cancer should be offered screening for BRCA1 so their health can be monitored from an early age.
During the study, 913 men underwent genetic testing for BRCA1 and results were received from 886 men. Four of the men tested were found to carry the faulty gene. Three out of the four men developed prostate cancer before the age of 65. From this, the researchers were able to conclude that men with prostate cancer have a one in 200 chance of having a faulty BRCA1 gene and that men who carry the faulty gene have an increased risk of developing the disease by 3.8 fold or, in other words, have almost a nine per cent risk of having prostate cancer by the age of 65.
Emma Malcolm, chief executive of the charity Prostate Action, said: “Early detection of prostate cancer can vastly improve the chances of successful treatment but at the moment there isn’t an effective way of screening for the disease. We’ve long known about the link between breast cancer and prostate cancer and this research confirms the likelihood of men developing prostate cancer from the inherited faulty BRCA1 gene. Once gene testing becomes faster and cheaper we may be able to identify those men at a higher risk of prostate cancer and monitor them from an early age.” Study author Professor Ros Eeles, from The Institute of Cancer Research, said: “The important thing about this result is that there are drugs that can target specific defects that occur with the BRCA1 mutation and this kind of result can open up the possibility of targeted medicines based on genetics.”
To read the Telegraph article in full, please click here.